Company intelligence / Profile preview
SiVEC Biotechnologies
- Ownership
- Private
- Development stage
- Other
Overview
SiVEC Biotechnologies has developed the BactPac platform for precise delivery of nucleic acids and proteins. Its pipeline includes SiVEC-IAV for influenza and SVC-KRAb for KRAS-mutant cancers.
- Therapeutic areas
- OncologyRare DiseasesPulmonology
- Modalities
- mRNAsiRNAProteins/NanobodiesCRISPR/Cas systemsLive biotherapeutic products
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on SiVEC Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SiVEC Biotechnologies.